Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma

Clinical Cancer Research

Volumn 22, Issue 22, 2016, Pages 5564-5573

  Chicard, Mathieu ^a,b   Boyault, Sandrine ^c   Daage, Leo Colmet ^a,b   Richer, Wilfrid ^a,b   Gentien, David ^b   Pierron, Gaelle ^b   Lapouble, Eve ^b   Bellini, Angela ^a,b   Clement, Nathalie ^a,b   Iacono, Isabelle ^c   Bréjon, Stéphanie ^c   Carrere, Marjorie ^c   Reyes, Cécile ^b   Hocking, Toby ^d   Bernard, Virginie ^b   Peuchmaur, Michel ^e   Corradini, Nadège ^c   Faure Conter, Cécile ^c   Coze, Carole ^f   Plantaz, Dominique ^g   Defachelles, Anne Sophie ^h   Thebaud, Estelle ⁱ   Gambart, Marion ^j   Millot, Frédéric ^k   Valteau Couanet, Dominique ^l   Michon, Jean ^b   Puisieux, Alain ^m   Delattre, Olivier ^a,b   Combaret, Valérie ^c   Schleiermacher, Gudrun ^a,b   more..

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c CENTRE LÉON BÉRARD   (France)

^d INSERM U900   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f TIMONE HOSPITAL   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h CENTRE OSCAR LAMBRET   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j HÔPITAL DES ENFANTS   (France)

^k POITIERS UNIVERSITY HOSPITAL   (France)

^l INSTITUT GUSTAVE ROUSSY   (France)

^m CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE DNA; DNA; UNCLASSIFIED DRUG; CIRCULATING TUMOR DNA;

ARTICLE; CANCER STAGING; CHROMOSOME BREAKAGE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA DETERMINATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENETIC ASSOCIATION; HUMAN; IGFR1 GENE; MAJOR CLINICAL STUDY; MYCN GENE; NEUROBLASTOMA; PRIMARY TUMOR; PRIORITY JOURNAL; ADOLESCENT; BLOOD; CHILD; CHROMOSOME ABERRATION; CLINICAL TRIAL; DNA MICROARRAY; FEMALE; GENETICS; GENOMICS; INFANT; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CIRCULATING TUMOR DNA; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENOMICS; HUMANS; INFANT; MALE; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84995960806     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0500     Document Type: Article

References (50)

1. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-37.
2. Combaret V, Audoynaud C, Iacono I, Favrot MC, Schell M, Bergeron C, et al. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res 2002;62:3646-8.
3. De Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNAas a liquid biopsy in breast cancer. Mol Oncol 2016;10:464-74.
4. Huang SK, Hoon DS. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol Oncol 2016;10: 450-63.
5. Jovelet C, Ileana E, Le Deley MC, Motté N, Rosellini S, Romero A, et al. Circulating cell-free tumor DNA(cfDNA) analysis of 50-genes by nextgeneration sequencing (NGS) in the prospective MOSCATO trial. Clin Cancer Res 2016;22:2960-8.
6. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369:2106-20.
7. Schleiermacher G, Janoueix-Lerosey I, Delattre O. Recent insights into the biology of neuroblastoma. Int J Cancer 2014;135:2249-61.
8. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012;483:589-93.
9. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013;45:279-84.
10. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 2013;45:12-7.
11. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-33.
12. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-97.
13. Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, et al. A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res 2011;17:792-804.
14. Ambros IM, Brunner C, Abbasi R, Frech C, Ambros PF. Ultra-high density SNParray in neuroblastoma molecular diagnostics. Front Oncol 2014; 4:202.
15. Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H, et al. Heterogeneity of the MYCN oncogene in neuroblastoma. Clin Cancer Res 2009;15:2085-90.
16. Bellini A, Bernard V, Leroy Q, Rio Frio T, Pierron G, Combaret V, et al. Deep sequencing reveals occurrence of subclonal ALK mutations in neuroblastoma at diagnosis. Clin Cancer Res 2015;21:4913-21.
17. Schramm A, Koster J, Assenov Y, Althoff K, Peifer M, Mahlow E, et al. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet 2015;47:872-7.
18. Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet 2015;47:864-71.
19. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 2010;28:3122-30.
20. Combaret V, Bergeron C, Noguera R, Iacono I, Puisieux A. Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma. J Clin Oncol 2005;23:8919-20.
21. Gotoh T, Hosoi H, Iehara T, Kuwahara Y, Osone S, Tsuchiya K, et al. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J Clin Oncol 2005;23:5205-10.
22. Combaret V, Brejon S, Iacono I, Schleiermacher G, Pierron G, Ribeiro A, et al. Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatr Blood Cancer 2011;56:757-61.
23. Combaret V, Iacono I, Bellini A, Bréjon S, Bernard V, Marabelle A, et al. Detection of tumor ALK status in neuroblastoma patients using peripheral blood. Cancer Med 2015;4:540-50.
24. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
25. Guimier A, Ferrand S, Pierron G, Couturier J, Janoueix-Lerosey I, Combaret V, et al. Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN. PLoS One 2014;9:e101990.
26. Combaret V, Iacono I, Brejon S, Schleiermacher G, Pierron G, Couturier J, et al. Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results. Cancer Genet 2012;205:657-64.
27. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009;100:1471-82.
28. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res 2002;12:996-1006.
29. Seshan V, Olshen A. DNAcopy: DNAcopy number data analysis. R package version 1.46.0; 2016. Available from: http://bioconductor.org/packages/DNAcopy/.
30. Hocking TD, Boeva V, Rigaill G, Schleiermacher G, Janoueix-Lerosey I, Delattre O, et al. SegAnnDB: interactive web-based genomic segmentation. Bioinformatics 2014;30:1539-46.
31. Bollet MA, Servant N, Neuvial P, Decraene C, Lebigot I, Meyniel JP, et al. High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. J Natl Cancer Inst 2008;100:48-58.
32. Waldman FM, De Vries S, Chew KL, Moore DHII, Kerlikowske K, Ljung BM. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst 2000;92:313-20.
33. Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, et al. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer 2012;107: 1418-22.
34. Combaret V, Hogarty MD, London WB, McGrady P, Iacono I, Brejon S, et al. Influence of neuroblastoma stage on serum-based detection of MYCN amplification. Pediatr Blood Cancer 2009;53:329-31.
35. Delacour H, Servonnet A, Perrot A, Vigezzi JF, Ramirez JM. [ROC (receiver operating characteristics) curve: principles and application in biology]. Ann Biol Clin 2005;63:145-54.
36. Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci 2000; 906:161-8.
37. Diaz LAJr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
38. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014;4:650-61.
39. Kurihara S, Ueda Y, Onitake Y, Sueda T, Ohta E, Morihara N, et al. Circulating free DNA as non-invasive diagnostic biomarker for childhood solid tumors. J Pediatr Surg 2015;50:2094-7.
40. Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, et al. Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol 2014;32:2727-34.
41. Wojtalla A, Salm F, Christiansen DG, Cremona T, Cwiek P, Shalaby T, et al. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets ofmedulloblastoma and neuroblastoma. PLoS One 2012;7:e47109.
42. De Nardo BD, Holloway MP, Ji Q, Nguyen KT, Cheng Y, Valentine MB, et al. Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 2013;8: e82513.
43. Ho WL, Chou CH, Jeng YM, Lu MY, Yang YL, Jou ST, et al. GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma. Oncotarget 2014;5: 12247-59.
44. Qi L, Toyoda H, Shankar V, Sakurai N, Amano K, Kihira K, et al. Heterogeneity of neuroblastoma cell lines in insulin-like growth factor 1 receptor/Akt pathway-mediated cell proliferative responses. Cancer Sci 2013;104: 1162-71.
45. Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet 2015;47:1411-4.
46. Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 2015;526:700-4.
47. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-54.
48. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013;59:211-24.
49. Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer 2013;133:346-56.
50. National Institutes of Health. Clinical Trials.gov. 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT01728155.